Gardner Lewis Asset Management’s Astria Therapeutics ATXS Stock Holding History

Gardner Lewis Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-739,565	Closed	-$9.68M	–	81
2025 Q4	$9.68M	Buy	+739,565	New	+$8.83M	2.45%	13

Gardner Lewis Asset Management's ATXS Position: Q1 2026 in Review

Gardner Lewis Asset Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 739,565 shares — an estimated $9.68M sold.

Gardner Lewis Asset Management first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $9.68M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Gardner Lewis Asset Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Gardner Lewis Asset Management sold 739,565 Astria Therapeutics shares in Q1 2026, an estimated $9.68M.
Gardner Lewis Asset Management first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Gardner Lewis Asset Management's Astria Therapeutics position peaked at $9.68M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Gardner Lewis Asset Management's 13F filing for Q1 2026, filed 8 May 2026.